Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Michael A. Desjardin net worth and biography

Michael Desjardin Biography and Net Worth

EVP of Horizon Therapeutics Public

Michael DesJardin joined Horizon in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He brings more than 39 years of experience in pharmaceutical development and before joining Horizon, he served as senior vice president of technical operations at Raptor, where he was responsible for quality, manufacturing, supply chain and pharmaceutical development. From July 2004 to March 2015, DesJardin served in various positions including senior vice president of product development at Jazz Pharmaceuticals plc. In addition, he was responsible for manufacturing, supply chain, program management and technical development in addition to leading the chemistry manufacturing and controls (CMC) diligence for Jazz's acquisitions of Orphan Medical Inc., Azur Pharma Ltd, EUSA Pharma and Gentium SpA.

Before Jazz, DesJardin served in positions of increasing responsibility at ALZA Corporation for nine years and spent 15 years at the Dow Chemical Company/Marion Merrill Dow working in both pharmaceutical and agricultural chemical development. DesJardin has led technical development and commercial manufacturing for chemical and pharmaceutical products, which incorporated several drug delivery technologies, including oral, implantable and injection systems. He is an inventor on 36 U.S. patents.

DesJardin received a Bachelor of Science in chemical engineering from the University of California, Berkeley, and is a registered professional engineer in the state of California.

What is Michael A. Desjardin's net worth?: The estimated net worth of Michael A. Desjardin is at least $9.58 million as of April 12th, 2022. Desjardin owns 82,346 shares of Horizon Therapeutics Public stock worth more than $9,576,840 as of April 19th. This net worth approximation does not reflect any other investments that Desjardin may own. Learn More about Michael A. Desjardin's net worth.
How do I contact Michael A. Desjardin?: The corporate mailing address for Desjardin and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Michael A. Desjardin's contact information.
Has Michael A. Desjardin been buying or selling shares of Horizon Therapeutics Public?: Michael A. Desjardin has not been actively trading shares of Horizon Therapeutics Public during the last quarter. Most recently, Michael A. Desjardin sold 20,214 shares of the business's stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $113.12, for a transaction totalling $2,286,607.68. Following the completion of the sale, the executive vice president now directly owns 82,346 shares of the company's stock, valued at $9,314,979.52. Learn More on Michael A. Desjardin's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Michael A. Desjardin Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/12/2022	Sell	20,214	$113.12	$2,286,607.68	82,346
2/26/2021	Sell	1,099	$91.83	$100,921.17	92,504
2/24/2021	Sell	15,944	$92.48	$1,474,501.12	92,504
2/11/2021	Sell	10,786	$90.00	$970,740.00	101,200
2/2/2021	Sell	4,530	$85.00	$385,050.00	111,986
12/10/2020	Sell	5,909	$69.64	$411,502.76	63,392

Michael A. Desjardin Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03